Myron W. Wentz Sells 4,144 Shares of USANA Health Sciences, Inc. (USNA) Stock

USANA Health Sciences, Inc. (NYSE:USNA) Director Myron W. Wentz sold 4,144 shares of the business’s stock in a transaction on Wednesday, May 23rd. The shares were sold at an average price of $120.86, for a total transaction of $500,843.84. Following the sale, the director now owns 11,025,753 shares in the company, valued at approximately $1,332,572,507.58. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Shares of USANA Health Sciences stock opened at $112.60 on Friday. The stock has a market capitalization of $2.83 billion, a P/E ratio of 27.73 and a beta of 0.76. USANA Health Sciences, Inc. has a 1 year low of $52.80 and a 1 year high of $121.15.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings results on Tuesday, April 24th. The company reported $1.19 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.05 by $0.14. The company had revenue of $292.00 million for the quarter, compared to analysts’ expectations of $268.93 million. USANA Health Sciences had a net margin of 6.47% and a return on equity of 27.92%. USANA Health Sciences’s revenue was up 14.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.91 EPS. analysts expect that USANA Health Sciences, Inc. will post 4.4 earnings per share for the current year.



A number of analysts have recently commented on the stock. TheStreet upgraded shares of USANA Health Sciences from a “c+” rating to an “a-” rating in a report on Tuesday, April 24th. Pivotal Research upped their price target on shares of USANA Health Sciences from $80.00 to $95.00 and gave the stock a “buy” rating in a research note on Wednesday, February 7th. Finally, ValuEngine upgraded shares of USANA Health Sciences from a “hold” rating to a “buy” rating in a research note on Wednesday, May 2nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $95.00.

A number of institutional investors have recently made changes to their positions in the stock. WINTON GROUP Ltd bought a new position in USANA Health Sciences in the 1st quarter worth about $661,000. Legal & General Group Plc boosted its stake in USANA Health Sciences by 40.2% in the 1st quarter. Legal & General Group Plc now owns 5,852 shares of the company’s stock worth $503,000 after purchasing an additional 1,678 shares in the last quarter. Robecosam AG bought a new position in USANA Health Sciences in the 1st quarter worth about $126,000. Millennium Management LLC boosted its stake in USANA Health Sciences by 314.6% in the 1st quarter. Millennium Management LLC now owns 84,445 shares of the company’s stock worth $7,254,000 after purchasing an additional 64,078 shares in the last quarter. Finally, Cubist Systematic Strategies LLC bought a new position in USANA Health Sciences in the 1st quarter worth about $2,423,000. Institutional investors own 48.85% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.

Insider Buying and Selling by Quarter for USANA Health Sciences (NYSE:USNA)

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply